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gression free survival (LPFS), event-free survival (EFS), toxicity, and
patterns of failure. The sample size was determined so that the 95%
confidence interval for the estimated 3-year OS would be  10% around
expected value of 80%.
Results: Between July 2004 and January 2007, 65 patients were registered
from 15 institutions. The patients characteristics were: male 45, female 20;
median age 79 (range 50-91); median tumor size 21 mm (range 10–30 mm);
adenocarcinomas 40, squamous cell carcinomas 21, others 4; and PS 0/1/2,
43/20/2. All patients completed the protocol treatment. As of November
2009, median follow-up of censored cases was 45.4 months. Of the eligible
64 patients, the 3-year OS was 76.0%, and the 3-year PFS, LPFS, and EFS
were 54.5%, 68.5%, 51.4%, respectively. Grade 3 toxicities observed were
chest pain in 1 (1.5%), dyspnea in 2 (3.1%), hypoxia in 1 (1.5%), and
pneumonitis in 2 (3.1%). No grade 4 and 5 toxicity was observed. A total of
25 patients showed progressions of diseases including 11 local progressions.
Conclusions: SBRT for operable stage I NSCLC is highly effective with
mild toxicity. This treatment has a potential to be an alternative to surgery
and should be considered as a treatment option especially in elderly patients.
Author Disclosure Block: M. Hiraoka: A. Employment; Kyoto University.
B. Research Grant; Varian Medical Systems, Mitsubishi Heavy Medal
Industry. F. Consulting/Advisory Board; Mitsubishi Heavy Medal Industry.
Y. Nagata: None. T. Shibata: None. H. Onishi: None. M. Kokubo: None.
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LACE-Bio: Cross-validation and Pooled Analyses of the Puta-
tive Prognostic/Predictive Biomarkers p27, p16 and cyclin E in
IALT, ANITA, JBR10 and CALGB 9633
R. Pirker1, V. Rousseau2, E. Paris2, M. S. Tsao3, S. Aviel-Ronen3, M.
Taron4, R. Kratzke5, E. Brambilla6, L. Seymour7, M. Filipits1, 1Department
of Medicine I, Medical University of Vienna, Vienna, Austria, 2Institute
Gustave-Roussy, Villejuif, France, 3University Health Network, Princess
Margaret Hospital, and the University of Toronto, Toronto, ON, Canada,
4Catalan Institute of Oncology, Badalona, Spain, 5University of Minnesota,
Minneapolis, MN, 6University Joseph Fourier, Grenoble, France, 7Queens
University, Kingston, ON, Canada
Purpose/Objective(s): Platinum-based adjuvant chemotherapy (CT) im-
proves survival in patients with completely resected non-small cell lung
cancer (NSCLC). Predictive markers may improve the selection of patients
for adjuvant CT. P27Kip1 (p27), p16INK4A (p16) and cyclin E (CyE) are
important regulators of cell cycle and potential markers of malignancy and
response to chemotherapy. Previous studies in the IALT trial suggested that
low p27 expression levels assessed by immunohistochemistry were predic-
tive of chemotherapy benefit. The aim of the present study was to cross-
validate the putative prognostic/predictive biomarkers p27, p16 and cyclin E.
Materials/Methods: LACE-BIO cross-validated the IALT p27 results in
669 patients (pts) from ANITA, JBR.10 and CALGB. Pooled analyses of
IALT and JBR10 examined prognostic and predictive values of p16 and CyE
in 1081 pts. High and low expression marker status was determined from
IALT by the medians of intensity x positivity rate scores for p27 and CyE,
and a score  1 for p16. Prognostic/predictive values of each marker for
overall survival (OS) and disease-free survival (DFS) were tested in a Cox
model stratified by trial and adjusted for clinical and pathological factors.
Results: 46% of pts had high p27 expression in their tumors, which was less
common in squamous cell carcinomas (SCC) and T2 tumors. For OS, p27
status was neither prognostic (HR 0.97, 0.77-1.22, p0.80), nor predictive of
adjuvant CT benefit (interaction p0.83, HR 0.83 vs. 0.87 for high and low
p27, respectively). P27 status was also not prognostic or predictive for DFS.
45% of pts had high CyE and 42% had high p16. High CyE was more
common in SCC (p0.0001) while high p16 was more common among
females (p0.0001) and adenocarcinomas (p0.0001). CyE and p16 were
neither prognostic (HR 0.98 and 0.96, respectively) nor predictive for OS
(interaction p0.20 and p0.95, respectively) and for DFS (interaction
p0.21 and p0.79, respectively).
Conclusion: The prognostic and predictive values of p27, p16 or cyclin E in
resected NSCLC were not confirmed. These results demonstrate the impor-
tance of robust validation of potential biomarkers prior to their use in clinical
practice. Supported by French Cancer League and Sanofi Aventis and
Canadian Cancer Society Research Institute.
Author Disclosure Block: R. Pirker, None; V. Rousseau, None; E. Paris,
None; M.S. Tsao, None; S. Aviel-Ronen, None; M. Taron, None; R.
Kratzke, None; E. Brambilla, None; L. Seymour, None;M. Filipits, None.
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Cytologic Evaluation of Stapled Lung Parenchyma Debris to
Determine Adequate Surgical Margins
T. Fabian1,2, J. A. Federico2, A. L. Mouhlas1, P. N. Fiedler2, 1Albany
Medical College, Albany, NY, 2Hospital of St. Raphael, New Haven, CT
Purpose/Objective(s): Pathologic evaluation of lung parenchyma margins is
limited and imprecise and at times results in incorrect interpretation of
surgical margins in NSCLC. We sought to evaluate staple line debris
cytology in patients undergoing sub-lobar resections to determine if this
novel technique is reliable in determining adequate or inadequate surgical
margins.
Materials/Methods: A prospective trial evaluating staple line debris cytol-
ogy in 72 patients undergoing diagnostic sub-lobar resection of the lung was
performed at a single institution between November 2007 and June 2009.
Spent stapler cartridges were mixed in 30cc of NS and served as the
cytologic margin. Cytologic margin and surgical specimen were then eval-
uated separately and blinded to one another. Patients in whom sub-lobar
resection was the planned definitive treatment were excluded from this study.
Results: Of 72 wedge specimens 41(57%) were NSCLC. In the 41 NSCLC
specimens initial cytologic evaluation was positive in 8 (20%), surgical
pathology margin was positive in 6(15%), both were positive in 3 (7%) of the
cases. Subsequent unblinded review of both specimens resulted in changed
interpretation of the surgical specimen from negative margin to positive
margin in 3 (7%) of 41 cases. Analysis of staple debris cytology compared
to histopathology demonstrated specificity (98%), sensitivity (78%), and
overall accuracy (94%) using this technique.
Conclusions: Cytologic evaluation of staple line debris is a highly sensitive
and specific test which alters the surgical margin interpretation in 7% of
cases of NSCLC. This could be considered an adjunct to traditional patho-
logic reporting. With increasing utilization of sublobar resection for NSCLC,
further study of the importance of staple line cytology is warranted.
Author Disclosure Block: T. Fabian: B. Research Grant; Covidien. D.
Speaker’s Bureau/Honoraria; Covidien. J.A. Federico: None. A.L.
Mouhlas: None. P.N. Fiedler: None.
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Bax Expression as a Predictive Marker of Survival Benefit in
Non-small Cell Lung Carcinoma Treated by Adjuvant Cispla-
tin-based Chemotherapy
E. Brambilla1, A. Bourredjem2, S. Lantuejoul1, M. S. Tsao3, J. P. Pignon2, R.
Kratzke4, R. Stahel5, J. Y. Douillard6, L. Seymour7, J. C. Soria8, 1Institut
National de la Sante´ et de la Recherche Medicale U823, Universite´ Joseph
Fourier, Department of Pathology, Grenoble, France, 2Biostatistics and
Epidemiology Unit , Institut Gustave Roussy, Paris, France, 3Princess
Margaret Hospital, University of Toronto, Toronto, ON, Canada, 4Depart-
ment of Medicine, The University of Minnesota, Minneapolis,, MN, 5Depart-
ment of Internal Medicine, University Hospital of Zu¨rich, Zu¨rich, Switzer-
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land, 6Department of Medicine, Centre R Gauducheau, St Herblain, France,
7NCIC Clinical Trials Group and Queen’s University, Kingston, ON, Can-
ada, 8Department of Medicine, Institut Gustave Roussy, Paris, France
Purpose/Objective(s): Because of its key role in mitochondrial apoptosis, it
is hypothesized that Bax may be a mediator of chemotherapy response. To
assess the impact of Bax expression on prognosis and benefit from platinum-
based adjuvant CT (ACT), we undertook a pooled analysis of two random-
ized trials (IALT, JBR10).
Materials/Methods: Bax immunohistochemical (IHC) expression was as-
sessed on slides obtained from formalin fixed paraffin embedded blocks,
using automated immunostaining on Ventana immunostainer and a score of
intensity x % of stained cells (1-300). The prognostic and predictive value for
benefit from ACT of Bax IHC on overall survival (OS) and disease-free
survival (DFS) was tested in a Cox model stratified by trial and adjusted for
clinical and pathological variables.
Results: Bax IHC was successfully performed in 1080 out of 1135 slides
(782 from IALT; 353 from JBR10). With a cut-off of score 90 (median), Bax
was positive in 58 % of IALT and 26 % of JBR10 cases. There was no
relation between Bax status and clinicopathological covariates including
histology. In the control and chemotherapy arms combined, Bax status was
not prognostic of OS or DFS in a Cox model adjusted for treatment, sex, age,
revised histology, N or T stage (p0.84 for OS; p0.55 for DFS). There was
no heterogeneity between the two trials (p0.08 for OS; p0.26 for DFS).
Predictive value of Bax status on OS was tested in a multivariate Cox
analysis. Bax status was significantly predictive for benefit from ACT on OS:
hazard ratio (HR) of death in Bax negative patients: 1.13 [95%CI: 0.89 -
1.45] p0.31; HR in Bax positive patients: 0.72 [0.56 - 0.91] p0.007; test
for interaction Bax/treatment: p0.009 and no heterogeneity (p0.14).Of
note, 3/4 of the events corresponded to the IALT trial. Similarly, Bax status
was significantly predictive for benefit of chemotherapy on DFS: HR in Bax
negative patients: 1.08 [0.86 - 1.36] p0.52; HR in Bax positive patients:
0.67 [0.53 - 0.84] p0.0006; test for interaction Bax/treatment: p0.004 and
no heterogeneity (p0.22). In view of these results the prognostic role of the
Bax marker was evaluated in the control group; borderline significance for a
small deleterious effect was observed on OS (HR  1.28 [1.00-1.64],
p0.05) with a small deleterious effect on DFS (HR1.33 [1.05 - 1.68],
p0.016); but this effect is not observed when subdividing the Bax marker
into four quartiles (p0.098 for OS and p0.11 for DFS).
Conclusion: In this pooled analysis of the IALT and JBR10 randomized trials,
Bax IHC was not significantly prognostic for survival, but was predictive of
survival benefit from adjuvant cisplatin-based chemotherapy in surgically re-
sected non small cell lung carcinoma. Supported by French Cancer League,
Sanofi-Aventis and the Canadian Cancer Society Research Institute.
Author Disclosure Block: E. Brambilla: None. A. Bourredjem: None. S.
Lantuejoul: None. M.S. Tsao: None. J.P. Pignon: None. R. Kratzke:
None. R. Stahel: None. J.Y. Douillard: None. L. Seymour: None. J.C.
Soria: None.
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Phase 2 Study of GI-4000 Vaccine as Adjuvant Consolidation
Therapy Following Resection of Patients With Stage I-III Ade-
nocarcinoma of the Lung With G12C, G12D, and G12V KRAS
Mutations
S. P. D’Angelo1, B. Park1, L. Krug1, C. Crevar1, C. Medina1, D. Sumner1, J.
Richman2, A. Cohn2, M. Kris1, C. G. Azzoli1, 1Memorial Sloan Kettering
Cancer Center, New York, NY, 2Globeimmune Inc., Louisville, CO
Purpose/Objective(s): All patients at MSKCC with adenocarcinoma of the
lung undergo reflex testing for EGFR and KRAS mutations at the time of surgical
resection. KRAS mutations occurred in 19% of resected lung adenocarcinomas
from 2006- 4/2009. GI-4000 is a recombinant, yeast-based vaccine (S. cerevi-
siae) engineered to express one of 4 mutated RAS oncoproteins.
Materials/Methods: This study gave GI-4000 as adjuvant therapy to pa-
tients with stage I-III lung adenocarcinomas and G12C, G12D, or G12V
KRAS mutations. All were disease free at their first post-treatment assess-
ment 1–4 months after completing all standard therapies. GI-4000 was given
for 3 weekly doses, then 6 monthly doses, then every 3 months for up to 3
years. The primary endpoint is vaccine-induced T cell responses documented
by interferon- (IFN ) ELISpot assay in peripheral blood mononuclear cells
(PBMCs) stimulated ex vivo with RAS peptide pools from the specific KRAS
mutation in the tumor specimens. Response criteria in baseline negative
subjects: at least one KRAS peptide pool with increase from baseline of 25
IFN  cells/106 PBMCs and at least 2x the assay background. Response
criteria in baseline positive subjects: baseline response of 25 IFN cells
/106 PBMCs and a  2 fold increase for that specific peptide pool on
treatment and a second product related peptide response of  25 IFN 
cells /106 PBMCs.
Results: We have accrued all 24 planned subjects. Women17, Stage
IA10, IB4, II2, III8, median age 67 (range 50-80), G12C15,
G12V3, G12D6, median # of doses per subject 9 (range 1-16). All
patients received every vaccination, except for one due to unrelated surgical
procedure. To date, there have been no serious adverse events related to
GI-4000. An interim analysis of the 10 subjects with at least 6 months of
immune sampling has been performed. Half of the subjects tested had either
a treatment emergent response to the ras mutation in their tumor (3/6, 50%),
or an improvement in a pre-existing baseline response to the mutation in their
tumor (2/4, 50%) based on pre-specified immunologic criteria.
Conclusions: MSKCC’s program of reflex (routine) testing of lung adeno-
carcinoma resection specimens for EGFR and KRAS mutations and the
EML4-ALK fusion gene permits the identification of patients for KRAS
specific therapy. The GI-4000 vaccine targeting mutated KRAS is immuno-
genic as an adjuvant “consolidation” therapy in patients with stage I-III lung
adenocarcinomas harboring KRAS mutations. These data warrant further
study of GI-4000 in KRAS mutant lung adenocarcinomas and other cancers
with these specific mutations. (Supported by Marty’s Fund, and GlobeIm-
mune, Inc.).
Author Disclosure Block: S.P. D’Angelo: None. B. Park: None. L. Krug:
None. C. Crevar: None. C. Medina: None. D. Sumner: None. J. Richman:
A. Employment; Globeimmune, Inc. A. Cohn: Globeimmune, Inc. M. Kris:
None. C.G. Azzoli: None.
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Prediction of Response to Gefitinib in NSCLC by EGFR Protein
Expression is Increased by a Novel EGFR Antibody and the Use
of AQUA Technology
M. W. Wynes1, C. Mascaux1, Y. Kato1, B. Reyna-Asuncion1, J. Zhao1, W.
Powell2, J. Ranger-Moore2, K. Yoshida3, N. Ikeda3, F. R. Hirsch1, 1Univer-
sity of Colorado Denver, Aurora, CO, 2Ventana Medical Systems, Inc,
Tucson, AZ, 3Tokyo Medical University Hospital, Tokyo, Japan
Purpose/Objective(s): Epidermal growth factor receptor (EGFR) protein
expression is not recommended for predicting response to EGFR tyrosine
kinase inhibitors. Previously reported data are based on antibodies (abs)
targeting the external domain of the receptor. We assessed the predictive role
of a novel ab targeting the intra-cellular domain of EGFR and compared it
with extra-cellular specific abs. Owing to its epitope specificity the intracel-
lular domain ab is purported to bind only activated EGFR. We further
compared immunohistochemistry (IHC) vs automated quantitative fluores-
cence analyses (AQUA) (HistoRx).
Material/Methods: We evaluated EGFR protein expression with two abs
specific for the extra-cellular domain (3C6, Ventana Medical Systems Inc;
31G7, Zymed) and one ab specific for the intracellular domain (5B7, VMSI)
using IHC and AQUA on tissue microarrays of tumors from 70 Japanese
non-small cell lung cancer (NSCLC) patients treated with gefitinib as
monotherapy for their recurrent disease after surgery at the Tokyo Medical
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University Hospital. We compared the predictive value of assessing EGFR
expression by IHC, scoring membrane versus membrane  cytoplasm, and
by AQUA, which automatically scores membrane  cytoplasm.
Results: EGFR expression evaluated by targeting the external domain of the
receptor, with the 3C6 ab and IHC, was not predictive of response to gefitinib
using either membrane staining (mean H score 34 vs 72, non responders vs
responders, respectively, p0.28) or both membrane cytoplasm (43 vs 76,
p 0.27) but, it was borderline when using the 31G7 ab with AQUA (8.2 vs
8.9, p0.0587). However, evaluation of EGFR expression using the internal
domain specific ab 5B7 was significantly predictive for response to gefitinib
using IHC and scoring membrane staining (185 vs 257, p0.0095), more
significant when considering both membrane  cytoplasm (179 vs 245,
p0.0035) and still slightly more significant when using 5B7 with AQUA
(11.2 vs 12.7, p0.0022). The positive predictive values for responders were
38, 40 and 50% and the negative predictive values were 83, 86 and 87%,
when evaluating membrane with IHC, membrane cytoplasm with IHC and
AQUA, respectively. Progression-free survival was not significantly differ-
ent between patients with high vs low EGFR expression (cut-off at the
median), for any ab with either detection method.
Conclusion: EGFR expression determined by an ab (5B7) specific for the
internal domain of the receptor is a significant and specific, but less sensitive,
predictor of response to gefitinib in this cohort of Japanese NSCLC patients
using IHC. Assessment of EGFR expression by AQUA increased the
predictive performance of this ab and should be further explored for pre-
dicting response to EGFR inhibitors in NSCLC.
Author Disclosure Block: M.W. Wynes, None; C. Mascaux, None; Y.
Kato, None; B. Reyna-Asuncion, None; J. Zhao, None; W. Powell,
Ventana Medical Systems, Inc, A. Employment; J. Ranger-Moore, Ventana
Medical Systems, Inc, A. Employment; K. Yoshida, None; N. Ikeda, None;
F.R. Hirsch, Ventana Medical Systems, Inc, C. Other Research Support.
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A Novel Prognostic Transcriptional Signature for Early Stage
Non-small Cell Lung Cancer
J. Ruiz, A. A. Miller, W. J. Petty, J. W. Chou, L. D. Miller, Wake Forest
University School of Med, Winston-Salem, NC
Purpose/Objective(s): Lung cancer is the leading cause of cancer deaths in
the U.S., with 170,000 new cases diagnosed annually. Non-small cell
carcinoma of the lung (NSCLC) accounts for 80% of lung cancer cases, and
has a 5-year survival rate of only 15%. While adjuvant chemotherapy is the
standard of care for patients with resectable stage II/IIIA disease, adjuvant
chemo is not routinely offered in the stage I setting, despite the fact that 40%
or more will relapse within 5 years post surgery. Currently, there are no
clinico-pathological markers with sufficient power or utility to distinguish
low- and high-risk cases of stage I NSCLC. A prognostic method capable of
further stratifying stage I patients could define a subpopulation with substan-
tially greater risk of disease recurrence that might show benefit from
chemotherapy or serve as rational candidates for the testing of novel
therapeutics in clinical trials.
Materials/Methods: We assembled a database of publicly available mi-
croarray expression profiles of stage I NSCLC tumors from four independent
studies that together comprised 300 stage IA/IB patients. After correcting
the RMA-normalized data for cohort-specific biases, we performed a statis-
tically-guided meta-analysis of the gene expression datasets to construct and
validate a gene-based classifier of prognosis.
Results: In a “training” cohort comprised of 120 patients, we identified a
6-gene prognostic classifier that stratified patients into low-, intermediate-
and high-risk groups with significantly different relapse rates. The 6-gene
stage I NSCLC classifier (aka, the “S1N” classifier) was then validated in a
179-patient “test” cohort. While the low- and intermediate-risk group sur-
vival times did not remain significantly different, the high-risk, poor outcome
group showed strong agreement with the training cohort - with a 5-year
relapse rate of 80%. We conclude that surgery followed by observation is
not sufficient treatment for these high-risk stage I patients.
Conclusion: The 6-gene S1N classifier identifies a high-risk group of stage
I patients for whom surgery alone is insufficient. High-risk patients identified
by the S1N classifier may benefit from the chemotherapy offered to later
stage patients.
Author Disclosure Block: J. Ruiz: None. A.A. Miller: None. W.J. Petty:
None. J.W. Chou: None. L.D. Miller: None.
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Identifying Clinically Relevant Cancer Genome Alterations in
Lung Cancer: The Clinical Lung Cancer Genome Project Ini-
tiative
R. Thomas, Max Planck Institute for Neurological Research, Cologne,
Germany
The Clinical Lung Cancer Genome Project (CLCGP) was launched in 2007,
bringing together scientists and physicians from a total of 13 medical and
academic centers from Europe, Australia and the U.S. to perform the
worldwide largest genomics analysis of clinically annotated lung cancer
specimens. By now, the CLCGP has collected over 1,700 clinically anno-
tated fresh-frozen lung cancer specimens of all subtypes. More than 900
specimens have already been extracted and genetic analyses have been
performed on several hundred, including analyses of tumor suppressor gene
and oncogene mutations and global analyses of chromosomal gene copy
number. Among the first findings were the discovery of frequent FGFR1
amplifications in squamous-cell lung cancer that associate with FGFR1
dependency (presented in a separate abstract) and many known as well as
previously unknown correlations of cancer genome alterations with clinical
outcome. Remarkably, the combination of global measures of copy number
and analyses of gene mutations in such a large sample set has enabled for the
first time to compare the prognostic value of individual alterations (e.g., MYC
amplification vs. EGFR mutation) and of combinations of such lesions.
Specifically, the groups of tumors characterized by mutations in the Ras-Raf
signaling pathway in general had a worse prognosis than those characterized
by alterations in receptor tyrosine kinase genes. By contrast, FGFR1-
amplified lung cancers had a poor prognosis that correlated with the ampli-
tude of the amplification. We note that our sample set is only biased by stage
(predominantly surgically removed early cancers) but not by other epidemi-
ological factors. Thus, while previous analyses of the prevalence of genetic
alterations were typically biased by the preferential accrual of epidemiolog-
ically defined subgroups (e.g., adenocarcinomas of never smokers that have
a higher chance of being EGFR-mutant, etc.), our cohort has enabled the
identification of the actual prevalence of such alterations in naturally occur-
ring cohorts of unprecedented size. Finally, the size of our collection
afforded performing an in-depth genomic analysis of rare lung cancer
subtypes as well. In small-cell lung cancer, we have identified novel
recurrent somatic mutations by whole-exome sequencing of tumor-normal
pairs. In summary, we have established a large collection of clinically
annotated lung cancer specimens; initial genomics analyses of these tumors
has revealed novel insights into lung cancer biology and genomic correlates
of clinical phenotypes.
Author Disclosure Block: R. Thomas, None.
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Effect of Race on Outcomes from Non-small Cell Lung Cancer
A. Ganti1,2, W. Gonsalves3, I. T. Aldoss4, P. T. Silberstein3,2, S. S. P.
Subbiah3, F. R. Loberiza1, 1UNMC, Omaha, NE, 2VA-NWIHCS, Omaha, NE,
3Creighton University Medical Center, Omaha, NE, 4University of Southern
California, Los Angeles, CA
Purpose/Objective(s): Lung cancer is the second most common cancer and
also accounts for the most cancer-related deaths. Although racial disparities
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in non-small cell lung cancer (NSCLC) outcomes in the United States have
been well documented, their reasons are unclear. A retrospective analysis of
patients included in the Veterans Affairs Central Cancer Registry (VACCR)
was conducted to evaluate if these disparities were a function of the disease
severity at presentation or a result of disparate treatments offered.
Materials/Methods: Patients diagnosed with NSCLC between January 1995
and February 2009, were identified. Data abstracted included age at diagno-
sis, gender, race, smoking history, disease stage, tumor grade, treatment and
overall survival. Demographic data of according to race were compared
using Kruskal-Wallis test or 2 test. Covariates associated with risk of
mortality were evaluated using multivariate Cox proportional hazards regres-
sion. A p-value of 0.05 was considered significant.
Results: Data from 95,425 patients were analyzed. Of these, 93,840 (98%)
were male and 78,207 (82%) were former or current smokers. These included
78,318 Caucasians (C), 16,433 African Americans (AA), 331 Asians (A) and
343 Native Americans (NA). C tended to have better risk features at
presentation compared to AA [stages I or II combined (22% vs. 20%); grades
I or II combined (18% vs. 16%)]. A larger proportion of C received
recommended stage appropriate treatment compared to AA. For stage I, more
C received surgery compared to other AA (46% vs. 40%; p0.001).
Similarly for stage IV, more C received chemotherapy compared to AA (23
vs. 19%; p0.001). On multivariate analysis, race, age, stage at diagnosis
and tumor grade were significantly associated with overall survival. AA had
a lower risk of mortality compared to C (HR: 0.93, 95% CI; 0.91–0.95). No
difference in risk of mortality were seen amongst A and NA when compared
to C. When disease stage was considered, AA had a better median survival
than C for stage III (9.1 vs. 8.6 months; p0.02) and IV (4 vs. 3.6 months;
p0.001). No differences in survival among patients with stages I or II were
seen according to race.
Conclusions: Although AA patients had a higher stage at presentation and
worse grade, they had better overall survival compared to C, despite not
receiving recommended stage appropriate treatment. This was more promi-
nent in stage III and IV, where chemotherapy is an integral part of treatment,
suggesting a better response to chemotherapy in AA compared to C. Genetic
differences responsible for these differences should be investigated in order
to better understand the effect of race on lung cancer biology and outcomes.
In a single payer system, without access to care barriers, the previously
described racial differences in lung cancer outcomes were not seen.
Author Disclosure Block: A. Ganti: None. W. Gonsalves: None. I.T.
Aldoss: None. P.T. Silberstein: None. S.S.P. Subbiah: None. F.R.
Loberiza: None.
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TNM Staging Compared to Veterans Administration Lung
Study Group Staging of Small Cell Lung Cancer- A Veterans
Cancer Registry Analysis
I. Aldoss1, T. Tashi2, W. Gonsalves2, p. silberstein1, A. Ganti3, R. Thota2,
S. Subbiah2, 1creighton University School of Medicine, omaha, NE, 2creigh-
ton University, omaha, NE, 3University of Nebraska, omaha, NE
Purpose/Objective(s): Prior studies have shown the feasibility of utilizing
the tumor, node, metastasis (TNM) staging system of non-small cell lung
cancer in patients with limited stage small-cell lung cancer (L-SCLC) into
well defined prognostic subgroups. We sought to evaluate the efficacy of the
TNM staging system in sub-classifying patients with L-SCLC into varying
prognostic groups.
Materials/Methods: Using the Veteran’s Affairs Central Cancer Registry
(VACCR) database, we conducted a survival analysis of patients with
L-SCLC (excluding patients with M1 and N3 disease). T category, N status
as per the sixth edition TNM staging, type of therapy, age, race, and tobacco
history was analyzed. Kaplan-Meier analysis was used to calculate survival.
Hazard ratios and 95% confidence intervals were calculated using Cox
proportional-hazard model.
Results: Of 24,252 cases of SCLC in VACCR database diagnosed between
1995 and 2008, 7841 cases were eligible. These included 14% (n  1064)
patients with stage IA, 15% (n 1172) stage IB, 2% (n 135) IIA, 8% (n
593) stage IIB and 28% (n 2212) patients with stage IIIA. Median survival
in years was 1.6 (95% CI, 1.47–1.72) for T1, 1.09 (95% CI, 1.04–1.13) for
T2, 0.9 (95% CI, 0.83–0.97) for T3 and 0.72 (95% CI, 0.68–0.75) for T4
tumors (p 0.0001). Increasing nodal stage also predicted for poor survival.
Median survival in years was 1.22 years (95 % CI, 1.18–1.29) for N0, 1.06
(95% CI, 0.98–1.14) for N1 and 0.85 (95% CI, 0.82–0.89) for N2 disease
(p  0.0001). Stage specific survival in years was 1.90 (95% CI, 1.76–2.11)
for stage IA, 1.21 (95% CI, 1.12–1.32) for stage IB, 1.41 (95% CI,
1.18–2.12) for stage IIA, 1.08 (95% CI, 0.97–1.21) for stage IIB, 0.96 (95%
CI, 0.92–1.01) for stage IIIA, (p  0.0001). Therapy was variable in this
population; only 32% of patients received chemoradiation which is the
standard of care for these patients. Median survival was 5.4 months (95%CI,
0.39–0.49) for patients who received no therapy, 10 months (95%CI,
0.80–1.89) for patients receiving chemotherapy only, 15 months (95%CI,
1.19–1.32) with chemoradiation, 11 months (95%CI, 0.85–1.02) with radio-
therapy alone, 43 months (95%CI, 3.09–4.52) for patients who underwent
surgery alone and 32 months (95%CI, 2.24–3.29) for patients who under-
went surgery and received adjuvant therapy (p 0.0001). In the multivariate
analysis, TNM staging, type of therapy received, tumor grade and age at
diagnosis were significantly associated with improved survival whereas race
and tobacco history showed no association with median survival.
Conclusion: TNM staging system is successful in stratifying patients with
limited SCLC into well defined prognostic groups.
Author Disclosure Block: I. Aldoss: None. T. Tashi: None.W. Gonsalves:
None. P. silberstein: None. A. Ganti: None. R. Thota: None. S. Subbiah:
None.
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PET/CT-guided Involved-field Intensity Modulated Radiation
Therapy for Limited-stage Small Cell Lung Cancer
J. Y. Chang, S. M. Shirvani, D. J. Stewart, B. S. Glisson, R. Komaki, M.D.
Anderson Cancer Center, Houston, TX
Purpose/Objective(s): The combination of intensity-modulated radiation
therapy (IMRT) with positron emission tomography (PET) in the treatment
of lung cancer allows radiation to be targeted to PET-positive areas of
disease while sparing normal structures and reducing treatment-related tox-
icity. Compelling evidence suggests that omitting elective nodal irradiation
does not compromise patient outcomes in non-small cell lung cancer, but
whether the same is true for limited-stage small-cell lung cancer (LS-SCLC)
remains controversial. We determined the frequency of elective nodal-field
failure in patients with LS-SCLC staged with PET/CT and treated with
involved-field IMRT.
Materials/Methods: Between 2005 and 2008, 62 patients with LS-SCLC at
M. D. Anderson underwent disease staging with PET and were subsequently
treated with an IMRT plan that did not intentionally include elective nodal
stations in the planning treatment volume (PTV). In most cases, the pre-
scribed dose was 45 Gy delivered in 30 twice-daily fractions (median dose
45 Gy in 30 fx, range 40.5 in 27 fx-63.8 in 35 fx) given with concurrent
platinum-based chemotherapy. These patients were analyzed in follow-up for
overall survival (OS), recurrence-free survival (RFS), and patterns of failure.
In-field failure (IFF) was defined as recurrence or progression within the
PTV. Extranodal failure (ENF) was defined as recurrence in initially unin-
volved hilar, mediastinal, or supraclavicular nodes. Survival was assessed
with the Kaplan-Meier method.
Results: Among the 62 patients included in the analysis, median age at
diagnosis was 63 y (range 39-86 y). The median follow-up time was 21
months (range 4-58 months) among all patients and 26 months (range 4-58
months) among survivors. Median OS time and 2-year actuarial OS and RFS
rates were 29 months, 63%, and 41%, respectively. Of the 32 patients with
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recurrence, 22 (69%) had metastatic disease and 10 (31%) had locoregional
failure. Among the latter group, 5 patients (16%) had IFF, 2 had ENF (6%),
and 1 had isolated ENF (3%).
Conclusions: In this cohort of 62 patients with LS-SCLC staged with PET and
treated with involved-field IMRT, isolated elective nodal failure occurred in only
1 patient (1.6%) and constituted 3% of observed failures. We conclude that
elective nodal stations can be safely excluded in patients with LS-SCLC staged
with PET for the purposes of dose escalation and reduced toxicity.
Author Disclosure Block: J.Y. Chang, None; S.M. Shirvani, None; D.J.
Stewart, None; B.S. Glisson, None; R. Komaki, None.
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Phase II Study of Sunitinib Monotherapy Following Irinotecan/
Carboplatin as First-line Treatment for Patients with Extensive-
Stage Small-Cell Lung Cancer
D. R. Spigel1, J. D. Hainsworth1, M. S. Rubin2, D. Shipley3, D. S. Thomp-
son3, E. T. Lubiner2, J. F. Eakle2, R. Quinn1, H. A. Burris1, A. Greco1, et al.,
1Sarah Cannon Rsrch Inst, Nashville, TN, 2Florida Cancer Institute, Fort
Myers, FL, 3Tennessee Oncology, PLLC, Nashville, TN
Purpose/Objective(s): Inhibition of angiogenesis may be effective in the
treatment of small-cell lung cancer (SCLC). Sunitinib, an oral agent that
inhibits the VEGF signaling pathway, may delay progression in sequence
with chemotherapy. The purpose of this phase II trial was to evaluate the
efficacy and safety of sunitinib monotherapy following 6 cycles of irinotecan
and carboplatin in patients with newly diagnosed extensive-stage SCLC.
Materials/Methods: Patients aged 18 years with previously untreated
extensive-stage SCLC were eligible. Additional criteria included: ECOG PS
0–1, no active brain metastases, and adequate organ function. Patients
received a maximum of six 28-day cycles of irinotecan (60mg/m2 days 1, 8,
15) and carboplatin (AUC  4, day 1), and were assessed for response every
8 weeks. After a maximum of 6 cycles of chemotherapy, patients with stable
disease or better proceeded to sunitinib monotherapy (25mg po daily) until
disease progression. The primary endpoint was 1-year overall survival (OS).
Results: Between 2/09 and 10/09, 34 patients (median age 65 years [range,
41-80]) were enrolled. 53% of patients were male, 47% had ECOG PS 0.21
patients (62%) completed 6 cycles of chemotherapy, and 17 (50%) initiated
sunitinib monotherapy (median duration: 3 months (range: 1–8 months).
After a median follow-up of 50 weeks (range: 37–68 weeks), 22 (62%) of the
patients remain alive; 6 patients are continuing on sunitinib monotherapy.
The objective response rate with chemotherapy was 59%, and an additional
20% had stable disease. 1-year OS was 54% and median time to progression
was 7.6 months. No grade 3/4 toxicities have occurred in 1 patient during
sunitinib monotherapy.
Conclusions: This phase II trial provides support for further study of
sunitinib maintenance therapy following platinum-doublet chemotherapy in
patients with extensive-stage SCLC. The 1 year OS of 54% is encouraging,
and a randomized trial would be appropriate to assess sunitinib’s impact
following chemotherapy.
D.R. Spigel: None. J.D. Hainsworth: None. M.S. Rubin: C. Other Re-
search Support; Research Funding- SCRI. ; F. Consulting/Advisory Board;
Multiple Advisory Boards. D. Shipley: None. D.S. Thompson: None. E.T.
Lubiner: None. J.F. Author Disclosure Block: Eakle: None. R. Quinn:
None. H.A. Burris: None. A. Greco: None.
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Phase II Study of Temozolomide for Relapsed Sensitive or
Refractory Small Cell Lung Cancer (SCLC)
M. C. Pietanza, C. S. Sima, M. R. Polley, D. K. Sumner, W. Travis, A.
Heguy, M. S. Ginsberg, A. Holodny, M. G. Kris, L. M. Krug, Memorial
Sloan-Kettering Cancer Center, New York, NY
Purpose/Objective(s): Alkylating agents have established efficacy in SCLC.
Temozolomide is an oral alkylating agent that penetrates the CNS with the
potential to treat brain metastases commonly seen in this disease. SCLC has
aberrantly methylated MGMT, which is predictive of improved outcomes in
patients with glioma treated with temozolomide. Anecdotal responses to
temozolomide in patients with SCLC have been observed. Thus, we designed
this phase II study of temozolomide in patients with relapsed SCLC.
Materials/Methods: Patients who have disease progression after one or two
prior chemotherapy regimens and a Karnofsky performance status  60%
are eligible. Temozolomide is administered at 75mg/m2/day for 21 days of a
28-day cycle. The primary endpoint is ORR, which is assessed separately in
two cohorts: sensitive-SCLC (S-SCLC) defined as relapse 60 days after
first-line therapy, or refractory-SCLC (R-SCLC) defined as progression
during first-line therapy, or within 60 days. In available tissue, we are
assessing MGMT promotor methylation status by PCR and MGMT expres-
sion by immunohistochemistry.
Results: The accrual is complete for the R-SCLC cohort (N16). 41 of the
planned 48 patients have been accrued in the S-SCLC cohort. Temozolomide
was second- and third-line treatment for 27 and 29 patients, respectively.
56% are women. 20 patients have progressive brain metastases, including 11
who had previously received brain radiation. Two of the 16 patients with
R-SCLC have had a PR (ORR  13%), one of whom was treated in third
line; 5 patients have had SD. This met the pre-defined criteria for efficacy. 36
patients are assessable for response in the S-SCLC cohort, with an ORR of
25% (1 CR, 8 PR), four of whom were treated in third line; 10 patients have
had SD. The ORR in both groups combined is 21%; while ORR is 26% and
18% in second- and third-line, respectively. Regressions in brain metastases
have been observed in 10 patients, including 5 patients with progression after
prior brain radiation. Toxicities include: grade 3/4 lymphopenia (30%); grade
3/4 neutropenia (4%); grade 3 thrombocytopenia (6%); grade 1/2 fatigue
(60%); grade 1/2 emesis (34%); and grade 3 rash/pruritis (8%). Partial
responses were noted in 29% of patients with MGMT promotor hypermeth-
ylation vs 9% with unmethylated tumors and in 43% of patients whose
tumors were negative for MGMT expression vs 17% with positive MGMT
expression (18 samples analyzed).
Conclusions: Single agent temozolomide has excellent efficacy in patients
with SCLC, including those with refractory disease, in third-line, and in
those with progressive brain metastases. This level of activity is comparable
to, or better than, that of currently approved therapies, with less toxicity.
Correlation of response with MGMT status is ongoing. Supported, in part, by
Merck.
Author Disclosure Block: M.C. Pietanza, Merck, C. Other Research
Support; C.S. Sima, None; M.R. Polley, None; D.K. Sumner, None; W.
Travis, None; A. Heguy, None; M.S. Ginsberg, None; A. Holodny, None;
M.G. Kris, None; L.M. Krug, Merck, C. Other Research Support.
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OPTIMAL: Phase III Study of First-line Erlotinib Versus Gemcit-
abine Plus Carboplatin (GC) in Chinese Patients (pts) With Acti-
vating EGFR Mutation-Positive Advanced Non-small Cell Lung
Cancer (NSCLC). On behalf of the OPTIMAL Investigators
J. Wang1, C. Zhou2, Y. Wu3, S. Lu4, L. Zhang5, Y. Zhang6, M. Ye7, J. Ma8,
J. Huang9, Q. Xiu10, 1Peking University School of Oncology, Beijjing Cancer
Hospital, Beijing, China, 2Shanghai Pulmonary Hospital, Tongji University,
Shanghai, China, 33Guangdong Lung Cancer Institute, Guangdong General
Hospital, Guangdong, China, 4Shanghai Chest Hospital, affiliated to Shang-
hai Jiao Tong University, Shanghai, China, 5Sun Yat-sen University Cancer
Center, Guangzhou, China, 6Zhejiang Cancer Hospital, Hangzhou, China,
7Renji Hospital, affiliated to Shanghai Jiao Tong University School of
Medicine, Shanghai, China, 8Harbin Institute of Hematology and Oncology,
Harbin, China, 9The First Affiliated Hospital of Suzhou University, Suzhou,
Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 7, December 2010 Abstracts
Copyright © 2010 by the International Association for the Study of Lung Cancer S507
China, 10Changzhen Hospital, the Second Military Medical University,
Shanghai, China
Purpose/Objective(s): Recent studies have demonstrated that epidermal
growth factor receptor tyrosine-kinase inhibitors (EGFR TKIs) are particu-
larly effective in NSCLC pts whose tumors harbor activating EGFR muta-
tions (mut ve). The phase III OPTIMAL study is a prospective evaluation
of first-line treatment with the EGFR TKI erlotinib versus GC in Chinese pts
with advanced NSCLC who have activating EGFR mut ve disease.
Materials/Methods: Chemonaı¨ve pts with advanced NSCLC and an ECOG
PS of 0-2, measurable disease and confirmed exon 19 deletions or exon 21
L858R point mutations in EGFR were eligible. Pts were randomized (1:1; no
cross-over was permitted) to receive erlotinib monotherapy (150mg/d) or
gemcitabine (1000mg/m2, d1  d8) plus carboplatin (AUC5, d1), every 3
weeks for up to 4 cycles, until unacceptable toxicity or progressive disease.
The primary endpoint was progression-free survival (PFS). Secondary end-
points included overall survival (OS), safety, quality of life, and biomarker
analyses, which are reported separately.
Results: Of the 549 pts screened, 186 had activating EGFR mutve disease.
Of these pts, 165 were randomized to erlotinib (n83) or GC (n82).
Baseline characteristics (including EGFR mutation type) were well-balanced
across both treatment arms. In the safety analysis (n155), no unexpected
adverse events (AEs) were reported in either arm. The incidence and severity
of treatment-related AEs and serious AEs (all grades) were lower in pts who
received erlotinib (n83; 79.5% & 2.4%, respectively) vs GC (n72; 94.4%
& 13.9%, respectively). A notably lower incidence of hematologic AEs (all
grades) was observed in the erlotinib arm, compared with the GC arm:
anaemia 4.8% vs 72.2%; neutropenia 6.0% vs 68.1%; thrombocytopenia
3.6% vs 63.9%, and febrile neutropenia 0% vs 1.4%, respectively. The
incidence of treatment-related rash and diarrhea was higher in the erlotinib
arm (rash 67.5% vs 19.4%; diarrhea 24.1% vs 2.8%, respectively), although
most cases were mild to moderate (grade 2) in severity (1 pt each for rash
and diarrhea [both grade 3] in the erlotinib arm; no grade 3-4 rash or diarrhea
in the GC arm). No dose reductions or treatment withdrawals were necessary
due to erlotinib-related rash. No interstitial lung disease-like events were
reported. Efficacy analyses are underway.
Conclusions: In chemonaı¨ve advanced NSCLC pts whose tumors had
activating EGFR mutations, first-line erlotinib (150mg/d) had a favorable
safety profile compared with GC. Full efficacy data will be presented at the
meeting.
Author Disclosure Block: J. Wang: None. C. Zhou: D. Speaker’s Bureau/
Honoraria; F. Hoffmann-La Roche. Y. Wu: C. Other Research Support; F.
Hoffmann-La Roche. ; D. Speaker’s Bureau/Honoraria; F. Hoffmann-La
Roche. S. Lu: None. L. Zhang: C. Other Research Support; AstraZeneca,
Aventis. ; D. Speaker’s Bureau/Honoraria; F. Hoffmann-La Roche, Astra-
Zeneca, Aventis. ; F. Consulting/Advisory Board; F. Hoffmann-La Roche,
AstraZeneca, GlaxoSmithKline. Y. Zhang: None. M. Ye: None. J. Ma:
Author Disclosure Block: None. J. Huang: None. Q. Xiu: None.
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Biomarker Associations With Survival for Refractory NSCLC
Patients Receiving Erlotinib Sunitinib in a Randomized Phase
2 Trial
H. J. M. Groen1, C. S. Harmon2, J. A. Williams2, F. Gao2, M. A. Socinski3,
F. Grossi4, C. Gridelli5, L. Tye2, R. C. Chao2, G. Blumenschein6, 1University
Medical Center Groningen, Groningen, Netherlands, 2Pfizer Oncology, La
Jolla, CA, 3University of North Carolina, Chapel Hill, NC, 4National
Institute for Cancer Research, Genova, Italy, 5S.G. Moscati Hospital, Avel-
lino, Italy, 6University of Texas MD Anderson Cancer Center, Houston, TX
Purpose/Objective(s): SUN1058 is a phase 2 study evaluating the efficacy
and safety of sunitinib (SU) 37.5 mg/day as a continuous daily dose plus
erlotinib (E) 150 mg/day vs. erlotinib (E) 150 mg/day plus placebo, in
patients (pts) with platinum-refractory advanced NSCLC (Stage IIIB/IV,
ECOG PS 0/1). Target enrollment was 126 pts to detect a 50% improvement
in PFS.
Materials/Methods: Biomarkers analyzed to investigate the influence of
tumor molecular characteristics on treatment outcome included EGFR pro-
tein expression, EGFR gene copy number, EGFR and KRAS mutational
status, and RNA levels for targets of sunitinib and angiogenesis-associated
proteins. Plasma soluble proteins levels were also assessed and included
VEGF-A, sVEGFR-2, sVEGFR-3 and sKIT. P-values shown are not ad-
justed for multiple testing. Tumor biomarker data were available for a subset
of pts.
Results: 132 pts were randomized. SU  E did not result in a statistically
significant increase in PFS compared with E alone (12.3 weeks vs. 8.5
weeks; unstratified HR  0.898, log-rank p0.05). When comparing PFS
between the two treatment arms in subgroups defined by tumor biomarkers,
no statistically significant differences were observed in subgroups defined by
either tumor EGFR status (protein expression: n48 and n48; gene copy
number: n31 and n29; and mutation: n25 and n20, for SU  E and
for E  placebo, respectively) or KRAS mutational status (n28 and n23).
For pts with low tumor PDGFR RNA levels, comparison of PFS favored
the SU  E (n16) vs. the E  placebo arm (n11; HR0.386, log-rank
1-sided p value: p0.0401). However for pts with high tumor PDGFR
levels no such difference was observed. Plasma sVEGFR-2 and sVEGFR-3
levels decreased and plasma VEGF-A levels increased compared with
baseline in the SU  E arm; no changes in these soluble proteins were seen
in the E  placebo arm. In the SU  E arm, longer OS was associated with
lower VEGF-C levels at baseline (HR2.093, log-rank p0.0347) and with
smaller reductions in plasma sVEGFR-3 at Cycle 2 Day 1 (HR0.439,
p0.04). In the E  placebo arm, longer PFS was associated with greater
baseline plasma sKIT levels (HR0.397, p0.0061) and with greater
reductions in plasma sVEGFR-3 at Cycle 2 Day 1 (HR2.7187, p0.0066)
and Cycle 3 Day 1 (HR2.919, p0.011).
Conclusions: Comparisons of PFS between the 2 treatment arms in sub-
groups defined by EGFR and KRAS status did not result in any statistically
significant differences in this phase 2 trial of SU  E vs. placebo  E in pts
with advanced refractory NSCLC. Plasma levels of baseline VEGF-C and
sKIT and of on-study sVEGFR-3 changes were associated with clinical
outcome. A difference was observed between the 2 treatment arms in PFS
favoring the SU  E arm for pts with low tumor PDGFR RNA levels.
Author Disclosure Block: H.J.M. Groen: B. Research Grant; Pfizer On-
cology. C.S. Harmon: E. Ownership Interest; Pfizer Oncology. F. Consult-
ing/Advisory Board; Consultant to Pfizer Oncology. J.A. Williams: A.
Employment; Pfizer Oncology. E. Ownership Interest; Pfizer Oncology. F.
Gao: A. Employment; Pfizer Oncology. E. Ownership Interest; Pfizer On-
cology. M.A. Socinski: B. Research Grant; Pfizer Oncology. F. Grossi:
None. C. Gridelli: D. Speaker’s Bureau/Honoraria; Roche. F. Consulting/
Advisory Board; Roche. L. Tye: A. Employment; Roche. E. Ownership
Interest; Roche. R.C. Chao: A. Employment; Roche. E. Ownership Interest;
Roche. G. Blumenschein: B. Research Grant; Roche.
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Randomized Phase 2 Study of Ixabepilone (ixa) Plus Carbopla-
tin (c) or Paclitaxel (p) Plus Carboplatin (c) in 3 Tubulin
Overexpressing Non-small Cell Lung Cancer
M. J. Edelman1, C. Schneider2, C. Tsai3, H. Kim4, E. Quoix5, A. Luft6, R.
Kaleta7, J. Mukhopadhyay7, L. Whitaker7, M. Reck8, 1University of Mary-
land Greenebaum Cancer Ctr, Baltimore, MD, 2Zentralklinik Bad Berka
Gmbh, Bad Berka, Germany, 3Taipei Veterans General Hospital, Taipei,
Taiwan, 4National Cancer Center, Goyang-Si, Korea, Republic of, 5Nouvel
Hopital Civil, Strasbourg, France, 6Leningrad Regional Clinical Hospital,
St. Petersburg, Russian Federation, 7Bristol-Myers Squibb, Wallingford, CT,
8Hospital Grosshansdorf, Grosshansdorf, Germany
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Purpose/Objective(s): Tumor expression of isoform 3T is an unfavorable
prognostic factor in several tumor types, including NSCLC treated with
standard tubulin-inhibiting chemotherapy agents. IXA is a semi-synthetic
epothilone B analog with low susceptibility to multiple tumor resistance
mechanisms in several tumor models. A randomized, international phase 2
study was conducted to explore if IXA-based chemotherapy can improve
prognosis in patients (pts) with stage IIIb/IV NSCLC whose tumors are
positive for 3T (3T).
Materials/Methods: 197 pts were randomized 1:1 and stratified by expres-
sion level of 3T status (positive/negative), to receive either IXA (32 mg/m2)
and C (AUC6) (N98) or P (200 mg/m2) and C (AUC6) (N99) on Day
1 of a 21 day cycle (cyc) for up to 6 cyc. The primary endpoint compared
PFS between IXA/C vs P/C in the 3T subgroup. The study was powered
to detect a hazard ratio (HR) of 0.58 using a two-sided 0.20 log-rank test
with 90% power. 3T expression was measured in central lab on baseline
tumor tissues using a standardized IHC assay developed by Dako; positivity
was pre-defined as 50% of tumor cells classified as 2 or 3.
Results: There were 104 3T and 93 3T negative (3T-) pts. 95 pts (52
3T and 43 3T-) received IXA/C and 96 pts (49 3T and 47 3T-)
received P/C. Median PFS (mPFS) in the 3T subgroup was 4.3 mo in both
arms (HR1.04 [80% CI: 0.78, 1.41], p0.853). In the III- subgroup,
mPFS was 5.8 mo for Ixa/C vs. 5.3 mo for P/C (HR0.78 [80% CI: 0.55,
1.10]). Independent of treatment arm, mPFS for pts with 3T was 4.27 mo
[80% CI: 3.61, 5.42] and 5.59 mo (80% CI: 4.63, 6.47) for 3T- disease
(HR1.32 [80% CI: 1.06, 1.64]). IXA/C generally exhibited a similar safety
profile to P/C. Peripheral neuropathy (all grades, grade 3/4) was numerically
lower in the IXA/C arm (36.8%, 0%) vs. the P/C arm (56.3, 7.3%); however,
a higher incidence of grade 3/4 anemia and thrombocytopenia (16.7% and
15.6%, respectively) were observed in the IXA/C arm relative to P/C (0%
and 1.1%, respectively).
Conclusions: 1) IXA/C chemotherapy produced similar PFS and response as
P/C in 3T and 3T- subgroups. 2) There was no predictive value of 3T
for clinical activity (PFS or response) between IXA/C and P/C. 3) 3T
patients had worse PFS relative to 3T-, regardless of treatment. 4) IXA/C
was generally well tolerated in this study of first-line advanced NSCLC.
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The Influence of Epidermal Growth Factor Receptor Mutation
on the Outcomes of NSCLC Patient After Radiotherapy
Q.Pang1,2, R. Komaki1, J. L. Lo´pez Guerra1,3, D. Gomez1, Y. Zhuang1, S. H.
Lin1, M. S. O’Reilly1, J. D. Cox1, Z. Liao1, 1The University of Texas M.D.
Anderson Cancer Center, Houston, TX, 2Tianjin Medical University Cancer
Hospital, Tianjin, China, 3Virgen del Rocı´o University Hospital, Seville,
Spain
Purpose/Objective(s): Epidermal growth factor receptor (EGFR) mutations
are highly predictive of response to EGFR tyrosine kinase (TK) inhibitors in
advanced non-small-cell lung cancer (NSCLC). However, we know little
about the relationship between EGFR mutations and outcomes after radio-
therapy. The purpose of this study is to evaluate the influence of EGFR
mutation on outcomes of NSCLC after radiotherapy.
Materials/Methods:We retrospectively reviewed the pathological reports of
NSCLC patients who underwent both EGFR testing and primary tumor
radiotherapy between 2007 and 2009 in M.D. Anderson Cancer Center.
Nucleotide sequencing of the kinase domain of EGFR (exons 18-21) was
performed using nested PCR amplification of individual exons. Clinical
outcomes were measured by local control, distant metastasis, and overall
survival.
Results: There were 111 patients who underwent EGFR test as part of their
pathological diagnostic procedure. The distribution of stages was: stage I in
4, stage II in 18, stage III in 82, stage IV in 7 patients. The median volume
of gross tumor was 82.91cm3, and the median dose of radiotherapy was
64.21Gy. Seventy-seven patients received concurrent chemoradiotherapy.
The most common chemotherapy agents were carboplatin and etoposide.
Thirty-four patients received radiotherapy only; and 19 patients received
molecular targeted therapy including Tarceva. Among the 111 patients who
had EGFR test, 24 had EGFR mutations. There were 2 cases with mutations
in exon 18. Ten cases had mutation in exon 19 deletions. 1 case had mutation
in exon 20. Eleven cases had mutation in exon 21. For the whole group, a
presence of EGFR mutations was not associated with local control, distant
metastasis, or overall survival compared to the wild-type group (p0.6737,
p0.7355, p0.5623) respectively. Since most of the mutations (21/24)
were in exons 19 and 21, we also compared the difference of outcomes after
radiotherapy between these two groups. There were no differences in patient
demographics, including age, sex, stage, gross tumor volume, radiation dose,
or treatment with EGFR-TK inhibitor between the two groups. There were
significant differences between exon 19 group and exon 21 group in rates of
local recurrence (0/10 vs 7/11, p0.0021).There was no significant differ-
ence in distant metastasis and survival between the two groups (p0,0870;
p0. 9187).
Conclusion: The most common loci of EGFR mutations are in exons 19 and
21 respectively. NSCLC with EGFR mutation in the exon 19 had more
favorable disease control locally after radiotherapy. This finding, when
validated in larger studies, could be used as a prognostic factor in designing
personalize radiotherapy for NSCLC.
Author Disclosure Block: Q. Pang, None; R. Komaki, None; J.L. Lo´pez
Guerra, None; D. Gomez, None; Y. Zhuang, None; S.H. Lin, None; M.S.
O’Reilly, None; J.D. Cox, None; Z. Liao, None.
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PET/CT and Outcome in Lung Cancer Treated With Stereotac-
tic Body Radiation Therapy
J. Y. Chang, X. Zhang, R. Komaki, T. Pan, P. Allen, P. Balter, H. Chuang,
M.D. Anderson Cancer Center, Houston, TX
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) is be-
coming a standard treatment for medically inoperable stage I non-small cell
lung cancer (NSCLC). However, the role of PET/CT in predicting clinical
outcome after SBRT remains controversial, mainly because of residual PET
avidity after treatment. We analyzed the prognostic value of PET/CT stan-
dardized uptake values (SUVs) in stage I and isolated lung-recurrent NSCLC
treated with SBRT.
Materials/Methods: Patients with biopsy-proven stage I (n68) or isolated
lung parenchyma recurrent/secondary (n60) NSCLC were treated with
image-guided SBRT in an approved phase II clinical study. All patients
underwent disease staging with PET/CT followed by 4-dimensional CT-
based planning and daily CT-on-rail or cone-beam CT-guided SBRT. The
prescribed dose was 50 Gy to the planning target volume, delivered in 4
consecutive days. Follow-up care comprised CT and clinical examination
every 3 months for 2 years plus PET at 1-3 and 3.1-6 months and annually
thereafter.
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